A pricing for everyone

Our pricing is based on the number of users. Whatever the size of your company, we have you covered !

Over 70 Pharma & Biotech clients Supporting PV since 2005 Over 3,000 users

1-Month Plan

  • 1-Month Plan
  • 3-Month Plan
  • Most popular
    1-Year Plan
1-Month Plan3-Month Plan
Most popular
1-Year Plan
72 €
180 €
16% OFF
600 €
24% OFF
Reports included1311
1 user72 €180 €600 €
2—5 users144 €360 €1 200 €
6—14 users240 €600 €2 000 €
15—49 users360 €900 €3 000 €
50 and + users480 €1 200 €4 000 €
Plan discount-16% OFF24% OFF
Buy lastest reportBuy 3-Month PlanBuy 1-Year Plan
  • 1-Month Plan
  • 1-Month Plan
1-Month Plan1-Month Plan
72 €
/1 user + taxes*
72 €
/1 user + taxes*
Reports included11
1 user72 €72 €
2—5 users144 €144 €
6—14 users240 €240 €
15—49 users360 €360 €
50 and + users480 €480 €
Plan discount--
Buy latest reportsLatest reports

3 Month Plan

  • 3 Month Plan
  • 3 Month Plan
3 Month Plan3 Month Plan
180 €
/1 user + taxes*
180 €
/1 user + taxes*
Reports included33
1 user180 €180 €
2—5 users360 €360 €
6—14 users600 €600 €
15—49 users900 €900 €
50 and + users1 200 €1 200 €
Plan discount16% OFF16% OFF
Buy 3 Month PlanBuy 3 Month Plan

1 Year Plan

  • 1 Year Plan
  • 1 Year Plan
1 Year Plan1 Year Plan
600 €
/1 user + taxes*
600 €
/1 user + taxes*
Reports included1111
1 user600 €600 €
2—5 users1 200 €1 200 €
6—14 users2 000 €2 000 €
15—49 users3 000 €3 000 €
50 and + users4 000 €4 000 €
Plan discount24% OFF24% OFF
Buy 1 Year PlanBuy 1 Year Plan

* Value Added Tax (VAT) may apply depending on the country where the Client is established, as defined in EU Directive 2006/112/EC (articles 44 and 196) and in the French Tax Code (CGI articles 259 and 283-2):

  • Business Clients established in France: French VAT (20%) applies
  • Business Clients established in other EU Member States: Clients are required to provide their EU VAT Number and to pay applicable VAT in their respective countries (reverse charge procedure).
  • Business Clients established outside the EU: Clients may be required to pay applicable VAT or Sales Tax equivalent in their country, if applicable.
  • Other clients: Please refer to our General Conditions.

Request free sample

Want to make sure our reports meet your expectations ? You can access a full sample report here to assess the value of our service.
Receive for free

Free alerts

The latest news on pharmacovigilance regulatory requirements in your mailbox, every month. 100 % free.

Let’s hear
What they say

  • For many years, my company has subscribed to Safety Observer

    It is a very valuable and structured tool. It is keeping us up to date with new and updated regulatory requirements so we can take appropriate actions to ensure compliance.
    EU-QPPV, Director of a Nordic-based pharmaceutical company 15-July-2022

  • Safety Observer serves as our company’s primary source for Regulatory PV updates.

    All PV employees have access and the comprehensive content in each issue is discussed on a monthly “Safety Observer Meeting”.
    EU-QPPV at a US-based biotech 30-June-2022

  • The Regulatory Intelligence Reports received monthly allow us to be more efficient in our regulatory monitoring

    The reports contain all the information necessary to meet our requirements. The summaries and links contained for each item make it a clear and practical document, allowing us to save a lot of time.
    Expanscience Laboratoires 30-June-2022

  • Our Safety Observer monthly review is part of our company’s safety specific Regulatory Watch process to ensure that changes in the regulatory landscape are captured and internal SOPs updated accordingly

    Lisa Skintemo, Pharmacovigilance Director at a small European-based Biotech company 01-July-2022

  • For five years now I have been reading the Safety Observer and will continue to do so.

    Even newsletters from large Pharmaceutical Associations cannot rival the in-depth coverage of such a long list of salient PV topics, as does the Safety Observer. The information contained is up-to-date, relevant to all decision makers in PV – and presented in a no-nonsense style that does not need precious time to understand the changes made: Succinct and relevant.
    Dr. Renald Hennig, Managing Director at SCRATCH Pharmacovigilance GmbH & Co. KG (and EU QPPV for a number of clients) 04-July-2022

  • As one of its earliest subscribers, I can testify of the high level of completeness and quality of this regulatory screening.

    Each month, it provides in one look all the necessary updates I require to perform my daily activities.
    Local Drug Safety and Medical Information Manager of the French Affiliate of an EU-based Pharmaceutical company 04-July-2022

  • I have discovered Safety Observer in 2016 and since then I am the most loyal fan of it.

    This magazine is able to replace the entire regulatory intelligence department in your organization. Subscription to Safety Observer is the easiest and most efficient way to keep up with the speed of safety regulation changes on a global level
    Associate Director of Medical Affairs, middle size CRO 11-July-2022

  • Subscribing to the Safety Observer has given me relevant updates in a concise, accurate and easy manner in order to be kept up to date in my day to day Quality Assurance activities internally and externally.

    The format has enabled easy understanding and the accessibility to the source document has made it easier to document my self training. I am extremely pleased with the service provided.
    Associate Director at a Global QA Service Provider 30-June-2022

  • Safety Observer is an effective and essential link in our regulatory intelligence,

    particularly in the constantly changing clinical research environment
    S.Laghouati, Head of the Pharmacovigilance Unit, Clinical Research Division, Gustave Roussy 18-July-2022

  • Safety Observer has proven to us to be a reliable and reputable resource allowing us to remain current on new regulatory guidance.  

    Safety Observer has also been instrumental in alerting us to crucial Drug Safety Signal Detection publications and literature, which have had a direct impact on improving and bolstering the attentiveness of our pharmacovigilance activities.  
    Synergy Research, Inc 01-August-2022